Parkinson disease
Therapeutic area
Neurology
Rare disease
Yes
- Definition
- A progressive degenerative disorder of the central nervous system characterized by loss of dopamine producing neurons in the substantia nigra and the presence of Lewy bodies in the substantia nigra and locus coeruleus. Signs and symptoms include tremor which is most pronounced during rest, muscle rigidity, slowing of the voluntary movements, a tendency to fall back, and a mask-like facial expression.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Parkinson disease
- Therapeutic area
- Neurology
- Parkinson disease
- PD
- Parkinson disease
- Parkinson's disease
- paralysis agitans
- All therapeutic areas
- Neurology
- Severity
- Moderate
- Genetic
- Hereditary
- MONDO ID
- MONDO:0005180
- Parent condition
- MONDO:0021095
Related records
Broader conditions (12)
- Basal ganglia disorder
- Brain disorder
- Central nervous system disorder
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Hereditary disease
- Hereditary neurological disease
- Human disease
- Nervous system disorder
- Parkinsonian disorder
Narrower conditions (27)
- Autosomal dominant Parkinson disease 1
- Autosomal dominant Parkinson disease 4
- Autosomal dominant Parkinson disease 8
- Autosomal recessive early-onset Parkinson disease 23
- Autosomal recessive early-onset Parkinson disease 6
- Autosomal recessive early-onset Parkinson disease 7
- Autosomal recessive juvenile Parkinson disease 2
- Autosomal recessive Parkinson disease 14
- Early-onset Parkinson disease 20
- Juvenile onset Parkinson disease 19A
- Juvenile-onset Parkinson disease
- Kufor-Rakeb syndrome
- Late-onset Parkinson disease
- Paralysis agitans, juvenile, of Hunt
- Parkinson disease 10
- Parkinson disease 12
- Parkinson disease 16
- Parkinson disease 17
- Parkinson disease 19B, early-onset
- Parkinson disease 21
Trials (4,491)
- " Visual Characterization of Parkinson's Patients and Oculomotor or Perceptual Therapy"
- "Parkinson AKTIV - Non-pharmacological Treatments in an Innovative Parkinson's Network"
- "Residual Kidney Function and Oxidative Stress in Incremental vs Standard Peritoneal Dialysis (2 Mexican Centers)"
- "Self-Compassion and Self-Efficacy in Parkinson's Disease: Associations With Symptoms, Function, and Quality of Life"
- "Turkish Validity and Reliability of the Heat Sensitivity Scale for Individuals With Parkinson's Disease"
- [11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease
- [18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy Patients
- [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor
- [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
- [18F]ACI-15916 PET in α-synucleinopathies
- [18F]F-DOPA Imaging in Patients With Autonomic Failure
- [18F]MC225-PET in Neurodegenerative Disease
- 10,000 Step Club: Community Walking Program for People with Parkinson's Disease
- 11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes
- 12 Weeks Vitamin D Supplementation and Physical Activity in PD Patients With DBS
- 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
- 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
- 123I-ALTROPANE® Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor
- 124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.
- 18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD
Approved drugs (39)
- Amantadine
- Amantadine hydrochloride
- Apomorphine
- Apomorphine hydrochloride
- Atropine sulfate
- Benztropine
- Benztropine mesylate
- Biperiden
- Bromocriptine
- Bromocriptine mesylate
- Cabergoline
- Carbidopa
- Entacapone
- Ethopropazine
- Ioflupane I 123
- Istradefylline
- Levodopa
- Methixene
- Opicapone
- Orphenadrine hydrochloride
Drugs in development (240)
- Acetaminophen Phase 1
- Acetylcysteine Phase 2
- Ambroxol Phase 3
- Amino acids Phase 1
- Amlenetug Phase 1
- Ampreloxetine Phase 3
- Aplindore Phase 2
- Arundic acid Phase 2
- Atomoxetine Early phase 1
- Atsm copper (II) Phase 1
- Bemdaneprocel Phase 2
- Benserazide Phase 3
- Bezisterim Phase 1
- Blarcamesine Phase 1
- Blarcamesine hydrochloride Phase 2
- Bornaprine Phase 2
- Brasofensine Phase 2
- Brexanolone Phase 1
- Brilaroxazine Phase 1
- Budipine Phase 2
Other linked drugs (20)
- Acamprosate
- Altinicline
- Capsaicin
- Clozapine
- Cycrimine
- Dalfampridine
- Dextrose
- Etrabamine
- Galantamine
- Lidocaine hydrochloride
- Lubiprostone
- Methixene hydrochloride
- Miridesap
- Orphenadrine
- Paeoniflorin
- Pittsburgh compound B
- Raclopride
- Rimabotulinumtoxinb
- Selegiline hydrochloride
- Terazosin hydrochloride